Source: ERJ Open Res, 7 (3) 00039-2021; 10.1183/23120541.00039-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Akira Yokoyama, Yukiyo Sakamoto, Taisuke Jo, Hirokazu Urushiyama, Hiroyuki Tamiya, Goh Tanaka, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga, Takahide Nagase. Pulmonary disease as a risk factor for transfusion-related acute lung injury. ERJ Open Res, 7 (3) 00039-2021; 10.1183/23120541.00039-2021

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary disease as a risk factor for transfusion-related acute lung injury in hospitalized patients: a nested case-control study in Japan Source: Virtual Congress 2021 – Mechanical ventilation and weaning Year: 2021 Neutrophilia is associated with the persistent parenchymal changes after acute lung injury Source: International Congress 2015 – Latest insights into chronic care Year: 2015 Novel swine model of transfusion-related acute lung injury (TRALI) Source: Annual Congress 2012 - The many roads to lung injury Year: 2012 Surfactant therapy for acute lung injury and other lung diseases Source: Eur Respir J 2003; 22: Suppl. 45, 210s Year: 2003 Delayed neutrophil apoptosis may predispose to lung injury in chronic lung disease of prematurity Source: Eur Respir J 2007; 30: Suppl. 51, 393s Year: 2007 Risk assessment in severe pulmonary hypertension due to interstitial lung disease Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Potential causes of acute deterioration in patients with interstitial lung disease Source: Annual Congress 2010 - Different patterns of interstitial lung disease Year: 2010 Mechanisms of acute lung injury Source: Annual Congress 2005 - In vivo - approaches to lung injury Year: 2005 Mechanisms of acute lung injury Source: Lung Science Conference 2004 - Application of our knowledge of the basic processes of lung inflammation in lung diseases Year: 2004 Acute exacerbation of interstitial lung diseases as a cause of respiratory failure. Our 3-years experience Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010 Pseudomonas and risk factor mitigation for chronic lung allograft dysfunction Source: Eur Respir J, 56 (4) 2001968; 10.1183/13993003.01968-2020 Year: 2020 Cumulative incidence and associated risk factor of chronic pulmonary infection after lung resection surgery for lung cancer Source: International Congress 2019 – Diagnosis of lung cancer Year: 2019 Hypoperfusion is the main risk factor for the development of non-tuberculous mycobacterial lung disease in CTEPH Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Chronic thromboembolic pulmonary hypertension in acute pulmonary embolism: A risk factor evaluation study Source: Virtual Congress 2020 – Pulmonary embolism Year: 2020 Predicting risk of mortality of chronic pulmonary aspergillosis Source: Virtual Congress 2020 – Aspergillosis and chronic lung infections Year: 2020 Pulmonary hypertension in chronic lung disease and hypoxia Source: Eur Respir J, 53 (1) 1801914; 10.1183/13993003.01914-2018 Year: 2019 Acute exacerbations of interstitial lung disease Source: Eur Respir Monogr 2016; 74: 117-131 Year: 2016 A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2014 – IPF and surroundings Year: 2014 Diffuse parenchymal lung diseases presenting with acute hypoxemic failure  Source: International Congress 2017 – Pulmonary emergencies year in review Year: 2017